Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Ipilimumab × Other solid neoplasm × Clear all

Phase

Status

Completed 14 Recruiting 5 Active not recruiting 5 Terminated 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 15 Genitourinary 3 Thoracic 2 Sarcoma 2 Other hematologic neoplasm 2 Gynecologic 2 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Lymphoid 1 CNS 1 Breast 1

Conditions

Interventions

Cisplatin 7 Pemetrexed 6 atezolizumab 5 Paclitaxel 3 Leucovorin 3 Etoposide 3 Carboplatin 3 vistusertib 2 tislelizumab 2 Temozolomide 2 Tegafur 2 Sorafenib 2 Irinotecan 2 Immunoenzyme Techniques 2 Gemcitabine 2 Filgrastim 2 Docetaxel 2 Cyclophosphamide 2 zirconium-89-trastuzumab 1 vandetanib 1 toripalimab 1 temsirolimus 1 tanespimycin 1 talazoparib 1 soblidotin 1 selinexor 1 sargramostim 1 roniciclib 1 rilotumumab 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡